查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1866553

疼痛管理药物市场－2025-2030年预测

Pain Management Drugs Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2030 年，疼痛管理药物市场将从 2025 年的 916.28 亿美元成长到 1,164.12 亿美元，复合年增长率为 4.90%。

疼痛管理市场是製药业的重要组成部分，旨在满足日益增长的有效止痛解决方案的需求。在全球人口老化、慢性病发病率上升以及外科手术数量增加的推动下，该市场预计将显着增长。然而，替代性止痛设备的涌现对市场扩张构成了挑战。

本报告检验了当前疼痛管理药物市场的需求、供应和销售趋势，以及影响该市场的最新发展。报告全面分析了关键驱动因素、阻碍因素和机会，并详细说明了区域产业趋势、政策和法规，帮助相关人员深入了解法规结构和市场动态。

我们的竞争情报是基于广泛的二手研究，包括产业协会调查、分析师报告、投资者报告、新闻稿和学术期刊，识别主要企业及其收入贡献。市场规模采用自下而上和自上而下的方法计算，并透过全球疼痛管理药物价值链相关人员的第一手资讯进行验证。我们全面的市场分析整合了各种资讯来源和专有资料集，并运用资料三角测量技术，提供准确的市场区隔和预测。我们透过分析叙述、图表和图形呈现检验，以帮助读者有效率地理解。预计2024年全球市场规模约785亿美元，2030年将达1,123亿美元，复合年增长率为6.2%。主要参与企业包括阿片类药物、非类固醇抗发炎药、皮质类固醇、抗忧郁症和抗惊厥药的领先生产商。

主要亮点

  • 老年人口不断增长：预计到 2050 年，老龄人口将达到 15 亿，这将推动对关节和慢性疾病疼痛管理药物的需求。
  • 慢性病流行：慢性病发病率不断上升，到 2024 年将影响全球 60% 的成年人，这正在推动市场成长。
  • 医疗保健支出：支出不断增长，尤其是在北美地区，这为先进的疼痛管理解决方案提供了支援。
  • 替代设备：止痛设备将在 2024 年占据 8% 的市场份额，从而抑制药品市场的成长。

成长要素

人口老化加剧（到2024年，65岁及以上成年人中将有20%患有慢性疼痛）显着推动了对疼痛管理药物的需求。类风湿性关节炎和癌症等慢性疾病的流行也促使人们需要标靶治疗，例如非类固醇抗发炎药和生物製药。不断增长的医疗费用支出（美国2024年的医疗保健支出将达到4.5兆美元）为获得先进治疗提供了支持。手术数量的增加（2024年全球手术量将增加6%）将推动术后止痛药物的需求。

抑制因素

经皮神经电刺激（TENS）等止痛设备的日益普及，加剧了与传统药物的竞争，并对药品销售造成影响。欧盟和美国将于2024年收紧阿片类药物使用监管，将因成瘾问题而限制处方笺。此外，研发新配方的高成本（平均高达10亿美元）也成为製造商面临的一大障碍。

細項分析

按药物类型划分：非类固醇消炎剂（NSAIDs）将占据主导地位，到2024年将占40%的市场份额，这主要得益于其在肌肉骨骼疼痛治疗中的广泛应用。生技药品在标靶慢性疼痛管理领域正经历快速成长。

依适应症分类：慢性下背痛最常见，其次是癌症和术后疼痛。类风湿性关节炎的需求也上升。

按地区划分：北美占 45% 的市场份额，这主要得益于美国的医疗保健支出和慢性病的流行。

区域分析

到2024年，北美将占据45%的显着市场份额，这主要得益于美国医疗保健领域的投资以及有效的疾病管理。亚太地区将以7.5%的复合年增长率成长，这主要得益于中国和印度慢性病病例的增加以及医疗基础设施的改善。欧洲将凭藉其支持性的医疗政策保持成长势头。

本报告为业内人士提供关于市场趋势、监管环境和竞争动态的关键洞察。报告探讨了替代医疗器材和监管限制等挑战，同时重点介绍了慢性病管理和创新製剂领域的机会。严谨的调查方法，结合一手和二手数据，确保了预测的可靠性，使相关人员能够驾驭复杂的市场环境，并优先考虑在这一重要的医药领域的投资。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2022-2024 年）和预测资料（2025-2030 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 依药物类型分類的疼痛管理药物市场

  • 介绍
  • 阿片类药物
  • 非类固醇消炎剂（NSAIDs）
  • 皮质类固醇
  • 乙酰胺酚
  • 抗忧郁症
  • 抗惊厥药
  • 局部麻醉剂
  • 其他的

第六章 依适应症分類的疼痛管理药物市场

  • 介绍
  • 癌症疼痛
  • 类风湿性关节炎
  • 慢性腰痛
  • 术后疼痛
  • 偏头痛/头痛疾病
  • 其他的

7. 依给药途径分類的疼痛管理药物市场

  • 介绍
  • 口服
  • 注射
  • 外用
  • 经皮吸收
  • 吸入
  • 其他的

第八章：按分销管道分類的疼痛管理药物市场

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房
  • 专科药房

9. 按地区分類的疼痛管理药物市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 台湾
    • 泰国
    • 印尼
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十一章：公司简介

  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Sanofi SA
  • Abbott Laboratories
  • Johnson & Johnson
  • Endo International PLC
  • Viatris Inc.
  • Purdue Pharma LP
  • Teva Pharmaceuticals Industries Ltd.

第十二章 分析方法

简介目录
Product Code: KSI061612046

The Pain Management Drugs Market is projected to climb from USD 91.628 billion in 2025 to USD 116.412 billion by 2030, fueled by a 4.90% CAGR.

The pain management drugs market is a critical segment of the pharmaceutical industry, addressing the growing need for effective pain relief solutions. Driven by an aging global population, increasing prevalence of chronic diseases, and rising surgical procedures, the market is poised for significant growth. However, the availability of alternative pain relief devices poses a challenge to market expansion.

This research examines current trends in demand, supply, and sales, alongside recent developments shaping the pain management drugs market. It provides a comprehensive analysis of key drivers, restraints, and opportunities, detailing industry trends, policies, and regulations across geographical regions to equip stakeholders with insights into the regulatory framework and market dynamics.

Competitive intelligence identifies major industry players and their revenue contributions, derived from extensive secondary research, including industry association studies, analyst reports, investor presentations, press releases, and journals. Market size for the overall sector and key segments was determined using bottom-up and top-down methodologies, validated with primary inputs from stakeholders in the global pain management drugs value chain. Comprehensive market engineering integrated data from diverse sources and proprietary datasets, employing data triangulation for accurate market breakdown and forecasting. Insights are presented through analytical narratives, charts, and graphics for efficient comprehension. The global market was valued at approximately USD 78.5 billion in 2024 and is projected to reach USD 112.3 billion by 2030, growing at a CAGR of 6.2%. Key players profiled include those leading in the production of opioids, NSAIDs, corticosteroids, antidepressants, and anticonvulsants.

Key Highlights

  • Geriatric Population Growth: An aging population, reaching 1.5 billion by 2050, drives demand for pain management drugs for joint and chronic conditions.
  • Chronic Disease Prevalence: Rising cases of chronic diseases, affecting 60% of adults globally in 2024, fuel market growth.
  • Healthcare Expenditure: Increased spending, particularly in North America, supports advanced pain management solutions.
  • Alternative Devices: Pain relief devices, gaining 8% market share in 2024, restrain drug market growth.

Growth Drivers

The growing geriatric population, with 20% of adults over 65 experiencing chronic pain in 2024, significantly boosts demand for pain management drugs. The prevalence of chronic diseases, such as rheumatoid arthritis and cancer, drives the need for targeted therapies like NSAIDs and biologics. Rising healthcare expenditure, with the U.S. allocating USD 4.5 trillion to healthcare in 2024, supports access to advanced treatments. Increasing surgical procedures, up 6% globally in 2024, heighten demand for post-operative pain relief.

Restraints

The growing adoption of pain relief devices, such as TENS units, competes with pharmaceutical solutions, impacting drug sales. Stringent regulations on opioid use, tightened in the EU and U.S. in 2024, limit prescriptions due to addiction concerns. High development costs for new formulations, averaging USD 1 billion, pose barriers for manufacturers.

Segmentation Analysis

By Drug Type: NSAIDs dominate with a 40% share in 2024, driven by widespread use for musculoskeletal pain. Biologics grow rapidly for targeted chronic pain management.

By Indication: Chronic back pain leads, followed by cancer and post-operative pain, with rheumatoid arthritis gaining traction.

By Geography: North America holds a 45% share, driven by U.S. healthcare spending and chronic disease prevalence.

Regional Analysis

North America commands a significant 45% market share in 2024, bolstered by U.S. healthcare investments and effective disease management. Asia Pacific grows at a 7.5% CAGR, driven by rising chronic disease cases and healthcare infrastructure development in China and India. Europe sustains growth through supportive healthcare policies.

This report equips industry experts with critical insights into market trends, regulatory landscapes, and competitive dynamics. It highlights opportunities in chronic disease management and innovative formulations while addressing challenges from alternative devices and regulatory constraints. The rigorous methodology, blending primary and secondary data, ensures reliable projections, enabling stakeholders to navigate complexities and prioritize investments in this essential pharmaceutical sector.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Drug Type

  • Opioids
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Antidepressants
  • Anticonvulsant drugs
  • Local Anaesthetics
  • Others

By Indication

  • Cancer Pain
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Migraine and Headache Disorders
  • Others

By Drug Delivery

  • Oral
  • Injectable
  • Topical
  • Transdermal
  • Inhalation
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

  • 5.1. Introduction
  • 5.2. Opioids
  • 5.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • 5.4. Corticosteroids
  • 5.5. Acetaminophen
  • 5.6. Antidepressants
  • 5.7. Anticonvulsant drugs
  • 5.8. Local Anaeshtehtics
  • 5.9. Others

6. PAIN MANAGEMENT DRUGS MARKET BY INDICATION

  • 6.1. Introduction
  • 6.2. Cancer Pain
  • 6.3. Rheumatoid Arthritis
  • 6.4. Chronic Back Pain
  • 6.5. Post-Operative Pain
  • 6.6. Migraine and Headache Disorders
  • 6.7. Others

7. PAIN MANAGEMENT DRUGS MARKET BY DRUG DELIVERY

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Injectable
  • 7.4. Topical
  • 7.5. Transdermal
  • 7.6. Inhalation
  • 7.7. Others

8. PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies
  • 8.5. Specialty Pharmacies

9. PAIN MANAGEMENT DRUGS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. United Kingdom
    • 9.4.2. Germany
    • 9.4.3. France
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. Japan
    • 9.6.3. India
    • 9.6.4. South Korea
    • 9.6.5. Taiwan
    • 9.6.6. Thailand
    • 9.6.7. Indosneisa
    • 9.6.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Novartis AG
  • 11.2. Eli Lilly and Company
  • 11.3. Pfizer Inc.
  • 11.4. GlaxoSmithKline plc
  • 11.5. Merck & Co., Inc.
  • 11.6. Sanofi S.A.
  • 11.7. Abbott Laboratories
  • 11.8. Johnson & Johnson
  • 11.9. Endo International PLC
  • 11.10. Viatris Inc.
  • 11.11. Purdue Pharma L.P.
  • 11.12. Teva Pharmaceuticals Industries Ltd.

12. RESEARCH METHODOLOGY